학술논문
Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts
Document Type
Article
Author
Beauverd, Yan; Morin, Sarah; Nabergoj, Mitja; Stephan, Caroline; De Ramon Ortiz, Carmen; Mamez, Anne-Claire; Mahne, Elif; Petropoulou, Anna; Giannotti, Federica; Ayer, Christian; Bruno, Benjamin; Bounaix, Laura; Anastasiou, Maria; Mappoura, Maria; Tran, Thien-An; Masouridi-Levrat, Stavroula; Chalandon, Yves
Source
Biology of Blood and Marrow Transplantation (Science Direct); 20240101, Issue: Preprints
Subject
Language
ISSN
10838791; 15236536
Abstract
•The disease risk comorbidity index (DRCI) is a recently published prognostic model combining the disease risk index (DRI) or the hematopoietic cell transplantation-specific comorbidity index (HCT-CI).•When evaluated in an independent cohort, with patients allografted with partially T cell depleted grafts, DRCI confirms its prognostic for overall survival, disease-free survival, and graft-versus-host disease-free/relapse-free survival but not for nonrelapse mortality and graft-versus-host disease.•Use of DRI and HCT-CI separately gives more accurate prognostic information and is more helpful to guide physicians and patients in HSCT choice than the DRCI model.